# Chemotherapy and Radiation Therapy With or Without Efaproxiral in Treating Patients With Stage III Non-Small Cell Lung Cancer

> **NCT00055887** · PHASE3 · WITHDRAWN · sponsor: **Spectrum Pharmaceuticals, Inc**

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** carboplatin
- **DRUG:** cisplatin
- **DRUG:** efaproxiral
- **DRUG:** gemcitabine hydrochloride
- **DRUG:** paclitaxel
- **DRUG:** vinorelbine ditartrate
- **PROCEDURE:** radiation therapy

## Key facts

- **NCT ID:** NCT00055887
- **Lead sponsor:** Spectrum Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2002-11
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study never started. No patients were enrolled.
- **Last updated:** 2013-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00055887

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00055887, "Chemotherapy and Radiation Therapy With or Without Efaproxiral in Treating Patients With Stage III Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00055887. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*